Oncomine Tumor mutation Burden (TMB)

Description

The Oncomine Tumor Mutation Load (TML) Assay is a method developed by Thermo Fisher Scientific to estimate Tumor Mutational Burden (TMB) using targeted next-generation sequencing. TMB, measured in mutations per megabase (mut/Mb), is a biomarker that indicates the number of mutations in a tumor’s genome and is increasingly used to predict response to immune checkpoint inhibitor therapies. The Oncomine TML assay offers a scalable solution for TMB assessment, particularly for formalin-fixed, paraffin-embedded (FFPE) research samples.